Adipocyte Fatty-Acid Binding Protein is Overexpressed in Cirrhosis and Correlates with Clinical Outcomes

Isabel Graupera1,2,3, Mar Coll2,3, Elisa Pose1,2, Chiara Elia1, Salvatore Piano1, Elsa Solà1,2,3,4, Delia Blayà2, Patricia Huelin1,2,3, Cristina Solé1,2,3, Rebeca Moreira1,2,3, Gloria de Prada1, Núria Fabrellas2,4, Adrià Juanola1, Manuel Morales-Ruiz2,3,5, Pau Sancho-Bru2,3, Candid Villanueva3,6 & Pere Ginès1,2,3,4

Fatty-acid-binding proteins (FABPs) are small intracellular proteins that coordinate lipid-mediated processes by targeting metabolic and immune response pathways. The aim of the study was to investigate plasma FABPs levels and their relationship with clinical outcomes in cirrhosis. Plasma levels of L-FABP1(liver and kidney), I-FABP2(intestine), and A-FABP4(adipocyte and macrophages) were measured in 274 patients with decompensated cirrhosis. Hepatic gene expression of FABPs was assessed in liver biopsies from patients with decompensated cirrhosis and in liver cell types from mice with cirrhosis. Immunohistochemistry of A-FABP4 in human liver biopsy was also performed. Plasma levels of FABPs were increased in patients with decompensated cirrhosis compared to those of healthy subjects (L-FABP1: 25 (17–39) vs 10 (9–17) ng/mL p = 0.001, I-FABP2: 1.1 (0.5–2.1) vs 0.6 (0.4–1) ng/mL p = 0.04 and A-FABP4: 37 (20–68) vs 16 (11–33) ng/mL p = 0.002), respectively. Increased A-FABP4 levels were associated with complications of cirrhosis, acute-on-chronic liver failure and poor survival. Hepatic A-FABP4 gene expression was upregulated in decompensated cirrhosis. Macrophages were the main liver cell that over-expressed A-FABP4 in experimental cirrhosis and increased A-FABP4 was found in macrophages of human biopsies by immunohistochemistry. A-FABP4 levels are increased in decompensated cirrhosis and correlate with poor outcomes. Liver macrophages appear to be the main source of A-FABP4 in decompensated cirrhosis.

Fatty-acid-binding proteins are small intracellular proteins of 14–15 KDa expressed in several tissues that coordinate lipid-mediated processes in cells by targeting metabolic and immune response pathways. At least 9 types of FABPs have been identified and they are named depending on the organ or tissue where they were discovered or are prominently expressed (liver, intestine, heart, fat…etc).1 FABPs share a characteristic three-dimensional configuration characterized by 10-stranded antiparallel β3-barrel structure with a fatty acid-binding pocket located inside its β-barrel. FABPs facilitate the transport of fatty acids to specific cell compartments where they exert their biological functions including, among others, membrane synthesis, oxidation, regulation of enzyme activity, and lipid-mediated transcriptional regulation.

Although FABPs were initially described as intracellular chaperones primary involved in lipid metabolism, FABPs effects are different according to tissues or cell types. The delivery of fatty acids to certain intracellular compartments in a specific tissue or cell leads to different protein-protein and protein-membrane interactions, which trigger functions that are tissue characteristic. Liver fatty-acid binding protein 1 (L-FABP1) is highly...
abundant in the liver but is also expressed in intestine, pancreas, kidney, lung, and stomach. L-FABP1 is the only FABP that can bind two long-chain fatty acids at the same time. Although the specific function of L-FABP1 in the liver is not completely known, it has been suggested that L-FABP1 would mainly act as a long-chain fatty acid transporter targeting the ligands to β-oxidation pathways. Intestinal fatty-acid binding protein 2 (I-FABP2), is mainly expressed in the epithelium of small intestine and contributes to lipid absorption and metabolism. Adipocyte fatty-acid binding protein (A-FABP4) is mainly expressed in adipocytes and macrophages and regulates adipocyte fatty-acid uptake and lipogenesis and delivery of lipids to nuclear receptors mediating nuclear transcriptional programs. Interestingly, in macrophages A-FABP4 modulates inflammatory responses and cholesterol ester accumulation. Specific actions of other FABPs are discussed elsewhere.

Besides its intracellular specific cell functions, FABPs are released into the circulation and increased plasma levels of different FABPs have been found in several clinical conditions and have been proposed as markers of tissue injury. For example, L-FABP1 plasma levels are increased in patients with acute rejection after liver transplantation; plasma levels of I-FABP2 are increased in intestinal ischemia and are a marker of intestinal epithelial damage and sepsis of abdominal origin; heart and brain FABPs (H-FABP3 and B-FABP7) are released into the circulation immediately after cardiac or brain cell damage; plasma A-FABP4 levels are increased in several metabolic (obesity, type-2 diabetes) and cardiovascular conditions (arterial hypertension, cardiac dysfunction and atherosclerosis) and have been shown to predict long-term cardiovascular events. Furthermore, A-FABP4 plasma levels are increased in critically-ill patients and correlate with poor prognosis, which suggests that A-FABP4 is not only a marker of metabolic syndrome but also an inflammatory marker of poor outcome.

Advanced cirrhosis is characterized not only by alterations in liver function, but also by abnormalities in many other organs including the gut and the immune system. Liver inflammation causes release of damage-associated molecular patterns (DAMPs). Moreover, intense alterations in the intestinal barrier, secondary to portal hypertension, lead to bacterial translocation and release of pathogen-associated molecular patterns (PAMPs). Both, DAMPs and PAMPs activate the immune system causing a persistent low-grade systemic inflammation that may contribute to cirrhosis progression, disease decompensation and development of acute-on-chronic liver failure (ACLF) syndrome.

Although the liver plays an important role in lipid metabolism, little is known about FABPs in cirrhosis. Hepatic gene expression of L-FABP1 has been shown to be down-regulated in non-alcoholic fatty liver disease (NAFLD) and A-FABP4 plasma levels have been associated with liver inflammation in NAFLD patients. Because advanced cirrhosis is characterized by abnormalities in different organs (liver, intestine, kidney, immune system...), we hypothesized that cirrhosis could be associated with alterations in FABPs plasma levels that could correlate with complications and disease outcomes. On this background, the aim of the present study was to investigate FABPs plasma levels and hepatic gene expression in decompensated cirrhosis and assess the relationship between FABPs and outcomes in cirrhosis. We studied three FABPs because of their potential pathogenic interest in cirrhosis: L-FABP1 and I-FABP2 because of their role in liver and intestinal damage and A-FABP4 because of its relationship with systemic inflammation and immune system.

Results

Characteristics of the patient population. 274 patients admitted to the hospital for complications of cirrhosis were included in this study. Demographic and clinical characteristics of the cohort are shown in Table 1. Patients had impaired liver function as reflected by increased serum bilirubin and INR and decreased serum albumin, with median MELD and Child-Pugh scores of 18 (IQ range:13–25) and 9 (IQ range:8–11), respectively. More than two thirds of patients had had previous complications of cirrhosis before the index hospitalization. At admission 183 patients (67%) had ascites, 126 (47%) acute kidney injury, 101 (37%) infection, 86 (31%) hepatic encephalopathy and 46 (18%) gastrointestinal bleeding. Sixty patients (19%) were admitted to the ICU, whereas the remaining patients were admitted to a regular ward.

Plasma FABPs levels and their relationship with complications of cirrhosis and ACLF. Plasma levels of all 3 FABPs were significantly increased in patients with decompensated cirrhosis compared to those of a group of healthy subjects, while only A-FABP4 plasma levels were significantly higher in patients with decompensated cirrhosis compared to patients with compensated cirrhosis (Fig. 1). In patients with decompensated cirrhosis, no differences were found among plasma levels of FABPs regarding sex or etiology of the disease. The plasma levels of the 3 FABPs showed a positive, albeit weak, correlation among each other. The best correlation was observed between L-FABP1 and I-FABP2 (r = 0.52, p < 0.001).

Table 2 shows FABPs plasma levels of all patients included in the study categorized according to the presence or absence of different complications of cirrhosis. Overall, the presence of any of the major complications of cirrhosis was associated with abnormal FABPs plasma levels. Specifically, increased levels of A-FABP4 were associated with all complications of cirrhosis, except for gastrointestinal bleeding. Results were less consistent with respect to L-FABP1 and I-FABP2.

Because patients with advanced cirrhosis are prone to develop bacterial infections and A-FABP4 has been proposed as an inflammatory marker, we wanted to assess the relationship between FABPs and bacterial infections in our series of patients. Table 3 shows the univariate analysis of patients with and without infections. As expected, patients with infection had higher levels of blood leukocytic, CRP and plasma IL-6 levels. The presence of infection was associated with high frequency of complications of cirrhosis such as hepatic encephalopathy, acute kidney injury and ACLF as well as more severe liver disease, as indicated by higher MELD and Child-Pugh score values, compared to patients without infection. With respect to FABP, A-FABP4 plasma levels were increased in patients with infection compared to patients without infection, while L-FABP1 and I-FABP2 plasma levels were significantly lower in infected patients. Furthermore, plasma A-FABP4 was the only FABP associated to the development of a new infection during hospitalization, with higher levels of A-FABP4 in those patients that...
Because there was a relationship between A-FABP4 levels and AKI and infections, we repeated the
relationship between plasma FABPs and survival.

We next investigated the relationship between plasma levels of FABPs and liver and kidney function, sys-
temic inflammatory parameters, and prognostic scores. L-FABP1 had a weak but positive correlation with AST
and ALT (r = 0.26; p < 0.001 for both), but did not correlate with liver function tests, such as bilirubin, INR or
albumin. I-FABP2 did not correlate with any of the parameters of liver function. Interestingly, A-FABP4 levels
correlated with serum bilirubin (r = 0.3; p < 0.001) and INR (0.36; p < 0.001). There was a significant direct cor-
relation between serum creatinine and plasma levels of FABPs (L-FABP1: r = 0.3, p > 0.001 for; I-FABP2: r = 0.2,
p < 0.001 and A-FABP4: r = 0.6, p < 0.001). Finally, only A-FABP4 correlated with cirrhosis severity scores, either
Child-Pugh or MELD (r = 0.38, p < 0.001 and r = 0.6, p < 0.001 respectively) (Supplementary Fig. 1). Regarding
relationship between plasma levels of FABPs and inflammatory parameters, only A-FABP4 showed a positive
correlation with IL-6 plasma levels (r = 0.23, p < 0.001) and leukocytes (r = 0.13; p = 0.03). Interestingly, when
infected patients were excluded, A-FABP4 levels positively correlated with plasma IL-6 levels (r = 0.27; p < 0.001)
and CRP levels (r = 0.21; p = 0.04).

One-hundred and thirteen out of the 274 patients (41%) had either ACLF at inclusion (95 patients) or
developed an infection during hospitalization compared to those patients that did not developed a new infection
[50 (26–107) vs 32 (08–64) ng/mL, respectively p < 0.001]. These differences persisted irrespective of the presence
or absence of an infection at inclusion. Among patients with infection, higher plasma levels of A-FABP4 were
associated with the presence of shock and ICU admission. On the other hand, no association was found between
the type of infection or the use of antibiotic treatment and A-FABP4 levels.

We developed an infection during hospitalization compared to those patients that did not developed a new infection
[50 (26–107) vs 32 (08–64) ng/mL, respectively p < 0.001]. These differences persisted irrespective of the presence
or absence of an infection at inclusion. Among patients with infection, higher plasma levels of A-FABP4 were
associated with the presence of shock and ICU admission. On the other hand, no association was found between
the type of infection or the use of antibiotic treatment and A-FABP4 levels.

During the 3-month follow-up period, 71 (26%) patients died (44 during hospitalization), 15 were transplanted, and only 1 patient was lost to follow-up. Three-month survival probability in the whole series was 73%. Variables at admission that were associated with 3-month survival in univariate analysis are shown in Table 4. Besides classical prognostic clinical and laboratory variables, plasma levels of A-FABP4 and L-FABP1 were significantly higher in patients who died at three months compared to those of survivors. Figure 2 shows the probability of 3-month mortality of the whole series of patients divided according to median plasma FABPs levels. Both, A-FABP4 and L-FABP1 were associated with mortality. However, in multivariate analysis only A-FABP4 levels were independently associated with 3-month mortality (Table 5). Because there was a relationship between A-FABP4 levels and AKI and infections, we repeated the

| Variable | Age (yr) | Gender (Male) | Etiology of cirrhosis. Alcoholic/Hepatitis C/Other | Previous complications of cirrhosis* | Chronic kidney disease** | Presence of ascites | Presence of encephalopathy | Norfloxacin prophylaxis | Antibiotic treatment | Treatment with beta-blockers | Serum bilirubin (mg/dL) | Serum albumin (g/L) | INR | Serum creatinine (mg/dL) | Serum sodium (mEq/L) | Blood leukocytes (10⁹/L) | C-reactive protein (mg/dL) | IL-6 (pg/mL) | Mean arterial pressure (mmHg) | MELD score | Child-Pugh score |
|----------|---------|--------------|-------------------------------------------------|-------------------------------------|--------------------------|-------------------|--------------------------|-----------------------|-------------------|-----------------------------|------------------|-----------------|-----|------------------|-------------------|-----------------|------------------------|----------------|---------------------|-----------------|
|          | 58 (52–67) | 177 (65) | 149/115/10 | 210 (76) | 45 (16) | 183 (67) | 86 (31) | 62 (23) | 158 (59) | 52 (19) | 2.4 (1.3–5.1) | 28 (25–32) | 1.1 (0.8–1.9) | 135 (131–137) | 5.7 (3.8–8.8) | 2.3 (0.9–5.0) | 110 (48–208) | 83 (75–90) | 18 (13–25) | 9 (6–11) |

Table 1. Demographic, clinical and laboratory data of the 274 patients at inclusion. Categorical variables are expressed as numbers and percentages (in brackets), continuous variables are expressed as median (inter-quartile range). MELD, model of end stage liver disease; *Ascites/Hepatic Encephalopathy/GI bleeding/SBP: 188/88/69/23, respectively **Parenchymal nephropathy in 26 patients and type-2 HRS in 24 patients, unknown in 2 patients.

**Relationship between plasma FABPs and survival.** During the 3-month follow-up period, 71
(26%) patients died (44 during hospitalization), 15 were transplanted, and only 1 patient was lost to follow-up.

Three-month survival probability in the whole series was 73%. Variables at admission that were associated with 3-month survival in univariate analysis are shown in Table 4. Besides classical prognostic clinical and laboratory variables, plasma levels of A-FABP4 and L-FABP1 were significantly higher in patients who died at three months compared to those of survivors. Figure 2 shows the probability of 3-month mortality of the whole series of patients divided according to median plasma FABPs levels. Both, A-FABP4 and L-FABP1 were associated with mortality. However, in multivariate analysis only A-FABP4 levels were independently associated with 3-month mortality (Table 5). Because there was a relationship between A-FABP4 levels and AKI and infections, we repeated the
multivariate analysis excluding patients with AKI and patients with infection. In both cases, the independent prognostic value of plasma A-FABP4 persisted (data not shown), indicating that the prognostic value of A-FABP4 was independent of the impairment of kidney function or presence of infection.

Hepatic gene expression of FABPs in patients with cirrhosis. We next sought to determine if the liver could be the source of plasma FABPs levels and therefore assess the hepatic gene expression of FABPs. We studied by quantitative real-time PCR the expression of A-FABP4, L-FABP1 and I-FABP2 in liver biopsies from a group of patients with decompensated cirrhosis with and without ACLF (n = 12 and n = 10, respectively). Biopsies from 6 healthy donors obtained at the time of living donor liver transplantation were also analyzed for comparison. As shown in Fig. 3a, hepatic A-FABP4 expression was markedly increased in patients with decompensated cirrhosis, with or without ACLF, compared to that of healthy subjects. By contrast, hepatic L-FABP1 expression was not increased in decompensated cirrhosis, either with or without ACLF (Fig. 3b). I-FABP2 was neither expressed in healthy livers nor in diseased livers.

Table 2. Plasma levels of FABPs according to the presence or absence of complications of cirrhosis at inclusion. FABPs levels are expressed as median (inter-quartile range). A-FABP4: adipocyte fatty-acid binding protein 4, L-FABP1: liver fatty-acid binding protein 1, I-FABP2: intestinal fatty-acid binding protein 2.

| Complication        | A-FABP4 (ng/mL) | L-FABP1 (ng/mL) | I-FABP2 (ng/mL) |
|---------------------|-----------------|-----------------|-----------------|
| Ascites YES         | 44 (26–87)      | 26 (18–40)      | 1.3 (0.7–2.3)   |
| Ascites NO          | 25 (13–42)      | 26 (18–44)      | 0.8 (0.4–1.7)   |
| Hepatic Encephalopathy YES | 44 (26–87)      | 26 (18–40)      | 1.3 (0.7–2.3)   |
| Hepatic Encephalopathy NO   | 25 (13–42)      | 26 (18–44)      | 0.8 (0.4–1.7)   |
| Aki YES             | 26 (15–37)      | 23 (15–35)      | 0.9 (0.4–1.8)   |
| Aki NO              | 1 (0.4–2)       | 1 (0.4–2)       | 0.9 (0.4–1.8)   |
| bleeding YES        | 42 (25–83)      | 30 (20–45)      | 1.3 (0.7–2.5)   |
| bleeding NO         | 21 (13–38)      | 24 (17–37)      | 1.1 (0.5–2)     |

Figure 1. Plasma levels of FABPs in patients with decompensated cirrhosis compared to patients with compensated cirrhosis and healthy subjects. Panel a shows plasma levels of adipocyte fatty-acid binding protein 4 (A-FABP4), panel b shows plasma levels of liver fatty-acid binding protein 1 (L-FABP1), and panel c shows plasma levels of intestinal fatty-acid binding protein 2 (I-FABP2). Values shown below the panels are plasma levels of FABPs expressed as median and inter-quartile range.

Hepatic gene expression of FABPs in patients with cirrhosis. We next sought to determine if the liver could be the source of plasma FABPs levels and therefore assess the hepatic gene expression of FABPs. We studied by quantitative real-time PCR the expression of A-FABP4, L-FABP1 and I-FABP2 in liver biopsies from a group of patients with decompensated cirrhosis with and without ACLF (n = 12 and n = 10, respectively). Biopsies from 6 healthy donors obtained at the time of living donor liver transplantation were also analyzed for comparison. As shown in Fig. 3a, hepatic A-FABP4 expression was markedly increased in patients with decompensated cirrhosis, with or without ACLF, compared to that of healthy subjects. By contrast, hepatic L-FABP1 expression was not increased in decompensated cirrhosis, either with or without ACLF (Fig. 3b). I-FABP2 was neither expressed in healthy livers nor in diseased livers.

Gene expression of A-FABP4 in liver cell populations. Given the increased A-FABP4 gene expression in the liver of patients with decompensated cirrhosis, we next sought to determine which cells were responsible for this increased expression. First, we confirmed in a mouse model of chronic liver disease and acute-on-chronic liver injury that A-FABP4 expression was increased (Fig. 3c). Next, we investigated the expression of A-FABP4 in distinct liver cell subpopulations, including hepatocytes, hepatic stellate cells, macrophages, lymphocytes, and neutrophils from mouse with acute-on-chronic liver injury. Interestingly, among all cell populations explored, macrophages were the only liver cells that markedly and significantly overexpressed A-FABP4 (Fig. 3d). These findings therefore confirm that the increased hepatic expression of A-FABP4 in an experimental model that resembles human disease derives from liver macrophages.

Immunohistochemistry of A-FABP4 in liver tissue of patients with decompensated cirrhosis. To further explore whether macrophages were the main liver cells expressing A-FABP4 in human disease, we performed immunohistochemistry of A-FABP4 in liver biopsies of patients with decompensated cirrhosis (n = 6). Figure 3e shows that macrophages were positive for A-FABP4 staining in the liver in healthy subjects as well as in patients with decompensated cirrhosis. A-FABP4 staining was increased in macrophages of patients with decompensated cirrhosis and ACLF as compared to healthy subjects.
**Table 3.** Characteristics of patients according to the presence or absence of bacterial infection at admission. Categorical variables are expressed as numbers and percentages (in brackets), continuous variables are expressed as median (inter-quartile range). MELD, model of end stage liver disease; MAP: mean arterial pressure; AKI, acute kidney injury, ACLF: acute-on-chronic liver failure; A-FABP-4: plasma adipocyte fatty acid binding 4; L-FABP-1: plasma liver fatty acid binding 1; I-FABP-2: plasma intestinal fatty acid binding 2.

|                          | Infected (n = 101) | Non-infected (n = 173) | p     |
|--------------------------|--------------------|------------------------|-------|
| Blood leukocytes (10⁹/L) | 6.9 (4.5–11.6)     | 5.4 (3.6–7.8)          | 0.001 |
| CRP (mg/dL)              | 3.9 (1.8–6.9)      | 1.7 (0.7–3.1)          | <0.001|
| IL-6 (pg/mL)             | 142 (74–272)       | 89 (45–168)            | <0.001|
| SIRS                     | 51 (51%)           | 72 (41%)               | 0.16  |
| Shock                    | 19 (19%)           | 16 (9%)                | 0.03  |
| Antibiotic treatment     | 101 (100%)         | 57 (33%)               | <0.001|
| MELD score               | 21 (13–28)         | 17 (12–22)             | 0.04  |
| Child-Pugh score         | 9 (8–12)           | 7 (7–10)               | 0.002 |
| MAP (mmHg)               | 81 (72–88)         | 83 (76–92)             | 0.02  |
| Ascites                  | 67 (66%)           | 116 (67%)              | 0.9   |
| Hepatic encephalopathy  | 42 (42%)           | 44 (25%)               | 0.004 |
| AKI                      | 56 (55%)           | 61 (35%)               | 0.03  |
| ACLF                     | 52 (52%)           | 61 (35%)               | 0.011 |
| Development of new infections | 21 (21%)      | 45 (26%)               | 0.38  |
| A-FABP-4 (ng/mL)         | 40 (26–89)         | 56 (18–63)             | 0.03  |
| L-FABP-1 (ng/mL)         | 22 (14–37)         | 27 (18–40)             | 0.012 |
| I-FABP-2 (ng/mL)         | 1.3 (0.7–2.1)      | 0.8 (0.3–1.8)          | 0.01  |

**Table 4.** Characteristics of patients at inclusion in the study according to 90-day survival. Categorical variables are expressed as numbers and percentages (in brackets), continuous variables are expressed as median (inter-quartile range). MELD, model of end stage liver disease; MAP: mean arterial pressure; AKI, acute kidney injury, ACLF: acute-on-chronic liver failure; A-FABP-4: plasma adipocyte fatty acid binding 4; L-FABP-1: plasma liver fatty acid binding 1; I-FABP-2: plasma intestinal fatty acid binding 2.

|                          | Alive (n = 203) | Dead (n = 71) | p     |
|--------------------------|-----------------|---------------|-------|
| Age (yr)                 | 58 (52–67)      | 60 (53–67)    | 0.896 |
| Gender (Male)            | 128 (63)        | 49 (69)       | 0.391 |
| Chronic kidney disease   | 33 (16)         | 12 (16)       | 0.516 |
| Presence of ascites      | 123 (61)        | 60 (84)       | <0.001|
| Presence of encephalopathy | 48 (24)       | 38 (53)       | <0.001|
| Serum bilirubin (mg/dL)  | 2.0 (1.1–3.4)   | 5.8 (2.6–22)  | <0.001|
| Serum albumin (g/L)      | 29 (26–32)      | 27 (25–32)    | 0.467 |
| INR                      | 1.5 (1.3–1.8)   | 1.8 (1.5–2.3) | <0.001|
| MELD score               | 16 (12–21)      | 27 (19–33)    | <0.001|
| Child-Pugh score         | 8 (7–10)        | 11 (10–12)    | <0.001|
| Serum creatinine (mg/dL) | 1.0 (0.7–1.6)   | 1.8 (1.0–2.8) | <0.001|
| Serum sodium (mEq/L)     | 136 (132–138)   | 131 (126–136) | <0.001|
| MAP (mmHg)               | 83 (77–92)      | 78 (72–86)    | <0.001|
| Blood leukocytes (10⁹/L) | 5.1 (3.5–7.8)   | 7.8 (5.4–12.6) | <0.001|
| CRP (mg/dL)              | 2.0 (0.7–4.8)   | 2.4 (1.7–6.3) | 0.062 |
| AKI                      | 78 (38)         | 50 (70)       | <0.001|
| ACLF                     | 51 (25)         | 44 (62)       | <0.001|
| A-FABP-4 (ng/mL)         | 30 (17–55)      | 64 (40–106)   | <0.001|
| L-FABP-1 (ng/mL)         | 24 (16–37)      | 28 (21–47)    | 0.005 |
| I-FABP-2 (ng/mL)         | 1.1 (0.5–2.0)   | 1.6 (0.6–2.3) | 0.2   |
Discussion

The results of the current study show that the plasma levels of three different FABPs, A-FABP4, L-FABP1, and I-FABP2, are increased in decompensated cirrhosis with respect to those of healthy subjects and correlate with important disease outcomes. Specifically, among the 3 FABPs analyzed, A-FABP4 plasma levels were those that showed a better correlation with clinical outcomes, specially complications of the disease, presence of ACLF, and short-term mortality. Findings from human liver biopsies demonstrated increased gene expression of A-FABP4, but not L-FABP1 and I-FABP2, in decompensated cirrhosis, which suggests that the increased plasma levels may be, at least in part, from hepatic origin. Finally, gene expression analyses in a mouse model of acute-on-chronic liver injury confirmed the increased hepatic expression of A-FABP4 and provided evidence that the liver macrophages are the cells mainly responsible for the increased hepatic expression, results that were further confirmed by the positive immunohistochemistry for A-FABP4 of macrophages in human diseased livers.

In recent years, evidence has been accumulated indicating that A-FABP4 is a very versatile protein that has important roles in lipid metabolism, macrophage function, and inflammation. A-FABP4 is one of the most abundant proteins in adipocytes and is an important regulator of lipid metabolism by acting on multiple integrated cellular pathways, involving peroxisome proliferator-activated-γ (PPAR-γ) and liver X receptor (LXR), to suppress adipose tissue lipogenesis and promote lipolysis. In addition to these effects, A-FABP4 also participates in inflammation by regulating cyclooxygenase-2 activity, promoting leukotriene A4 stability, and acting on a number of other intracellular pathways leading to increased synthesis of inflammatory mediators. A-FABP4 also participates in inflammation by regulating cyclooxygenase-2 activity, promoting leukotriene A4 stability, and acting on a number of other intracellular pathways leading to increased synthesis of inflammatory mediators. Knockout models of A-FABP4 exhibit changes in lipid compositions and metabolism and are resistant to chronic inflammation. On the other hand, expression of A-FABP4 in macrophages is induced during differentiation from monocytes and A-FABP4 is mainly involved in inflammatory responses through activation of the IKK-NF-κB and JNK-AP-1 pathways. Moreover, A-FABP4-deficient macrophages have impaired basal and stimulated expression of inflammatory cytokines, including monocyte-chemoattractant protein-1 (MCP-1) and tumor necrosis factor-α (TNF-α) as well as decreased IKK-NF-κB activity.

Table 5. Cox regression analysis of 90-day transplant-free survival. HR, hazard ratio; CI, confidence interval; AUROC 0.833. Variables included in the model: MELD, ascites, hepatic encephalopathy, leukocyte count, L-FABP1, A-FABP4, acute kidney injury, ACLF. *A-FABP4 was not introduced in the model as a continuous variable because it did not have a normal distribution and there was no linearity between hazard ratios of different quartiles. A categorical distribution with the median value was used instead.

| Variable                              | HR (95% CI)         | p     |
|---------------------------------------|---------------------|-------|
| Leukocytes (10⁹/L)                    | 2.2 (1.2–2.8)       | < 0.001 |
| Hepatic Encephalopathy                | 2.0 (1.2–3.4)       | 0.02  |
| MELD                                  | 1.1 (1.05–1.11)     | < 0.001 |
| A-FABP4 > 37.2 ng/mL*                 | 2.2 (1.2–4.1)       | 0.016 |

Figure 2. 90-day probability of mortality in all patients categorized according to median values of FABPs. A-FABP4: adipocyte fatty-acid binding protein 4, L-FABP1: liver fatty-acid binding protein 1 and I-FABP2: intestinal fatty-acid binding protein 2. Units of median values of FABPs are expressed in ng/mL.
index, insulin resistance, and dyslipidemia. Other studies have shown that plasma A-FABP4 levels correlate with important clinical outcomes including cardiovascular complications and survival. On the other hand, increased A-FABP4 have also been reported in patients with acute critical illnesses and are associated with poor survival.

The findings of the current study showing that patients with decompensated cirrhosis have increased plasma levels of A-FABP4 that correlate with disease complications, infections, ACLF, and survival are in keeping with those of studies in patients with chronic inflammatory conditions. Findings seem to be quite specific for A-FABP4 and not associated with other members of the FABPs family because correlation with disease outcomes of L-FABP1 or I-FABP was less consistent or not existent. The results of our study therefore support the current hypothesis of cirrhosis progression that proposes that both liver and systemic inflammation have a major role in disease progression, from acute decompensation to ACLF, and mortality. Liver inflammation in chronic liver diseases is mainly orchestrated by resident macrophages and infiltrating activated monocytes that promote fibrosis and disease progression. In that regard, it has been shown that plasma markers of macrophage activation, like sCD163 and soluble mannose receptor (sMR), are associated with the presence of ACLF and correlate with prognosis, suggesting an important role of liver macrophages in cirrhosis progression and ACLF development. Interestingly, we found that hepatic expression of A-FABP4 in human liver tissue was increased in patients with decompensated cirrhosis with and without ACLF. Furthermore, liver macrophages from a mouse model of acute on chronic liver injury were the main source of hepatic expression of A-FABP4, findings that were confirmed by the positive A-FABP4 staining of macrophages in patient’s liver tissue. All these findings point towards a role of liver macrophages in driving inflammation and disease progression and ACLF development. With respect to systemic inflammation, increasing evidence suggests that patients with advanced cirrhosis have a marked systemic inflammatory response with increased leukocyte count, C-reactive protein (CRP) levels, and pro-inflammatory cytokines which is independent of the presence of infections and correlates with prognosis. Moreover, it has been shown that this systemic inflammatory reaction, particularly in ACLF, is characterized by alterations in the expression of several cytokines involved in monocyte and macrophage migration. In the current study, plasma A-FABP4 levels correlated with infections and inflammatory parameters and increased levels of A-FABP4 were associated with development and severity of second infection. It is worth noting that the correlation between A-FABP4 plasma levels and plasma IL-6 and CRP persisted in patients without infections. Moreover, A-FABP4 was an independent prognostic factor at multivariate analysis even in non-infected patients. All these data suggest that A-FABP4 levels could be an inflammatory marker of decompensated cirrhosis as it has been shown in Figure 3.
and intra-assay variation for plasma FABPs were lower than 10 and 15%, respectively.

was measured with human ELISA IL-6 kit (Diasource; Louvain-la-Neuve, Belgium). Coefficients of inter-assay

the Quantikine ELISA human A-FABP4 kit (R&D Systems, Minneapolis, USA), respectively. Interleukin-6 (IL-6)

until analysis. L-FABP1, I-FABP2 and A-FABP4 were measured with the human L-FABP1 ELISA kit (Hycult

CCl4. Animal procedures complied with the institution’s guidelines, received human care and were approved

by the administration of lipopolysaccharide (LPS, Sigma-Aldrich) 10 mg/kg on the chronic damage caused by

(n1:4 in corn oil) at dose of 0.5 ml/kg body weight twice per week for a total of 5 injections (n = 5). Mice aged 8–10 weeks were subjected

study was performed in patients with cirrhosis hospitalized for management of an acute decompensation in a tertiary care hospital, with high propor-
\text{tion} \text{ of patients admitted to ICU (19%)}). Therefore, whether similar results could be obtained in a less severe

population is not known. However, it is important to remark that inclusion of patients with severe liver disease,

such as those with ACLF is important to explore the whole spectrum of disease progression. In our study, we only

measured FABPs plasma levels in a single time point and unfortunately, we do not have repeated measurements
to evaluate whether changes in plasma levels occur over time and bear relationship with disease progression or

improvement. This would have to be addressed in future studies. Finally, we measured only 3 out of the 9 FABPs

known. We selected those FABPs that we anticipated could have a more prominent role in patients with cirrhosis.

Therefore, we do not know whether other FABPs could be related to disease outcomes in cirrhosis.

In summary, the results of the current study indicate that plasma A-FABP4 levels are increased in decompensated cirrhosis and correlate with hard clinical outcomes, specifically complications of the disease, ACLF, and mortality. Results from gene expression in the liver indicate that A-FABP4, but not the liver-associated type L-FABP1, is increased in the cirrhotic liver tissue and liver macrophages appear to be the cell type responsible for this increased gene expression. Our results are consistent with a major role of inflammation in cirrhosis progression and clinical outcomes.

Methods

Study population. This is a prospective study of 274 consecutive patients with cirrhosis hospitalized for management of an acute decompensation of the disease at the Liver Unit of Hospital Clinic of Barcelona. These patients were included in a prospective investigation assessing mechanistic factors and markers of disease progression in cirrhosis between 2009 and 2012. Patients had their clinical information collected into a specific database and plasma and urine samples were taken at admission and stored into a biobank (Biobanco Hepatorenal R11-0602-054). All consecutive patients with cirrhosis admitted to the hospital were included in the biobank database except for the following: 1/patients with hepatocellular carcinoma outside the Milan criteria; 2/patients admitted to the day hospital for elective diagnosis or therapeutic procedures; 3/patients previously treated with liver and/or kidney transplantation; 4/patients on chronic hemodialysis; and 5/refusal of informed consent. All patients gave written informed consent for data and sample collection and analytical assessment. The protocol was approved by the Institutional Review Board of the Hospital Clinic of Barcelona and all experiments were performed in accordance with relevant guidelines and regulations. A group of 13 patients with compensated cirrhosis and 13 healthy subjects were also studied for comparison.

The diagnosis of cirrhosis was made using standard criteria either with liver biopsy or combination of clinical, analytical, and ultrasonographic findings. The diagnosis of ascites, hepatic encephalopathy, bacterial infections, gastrointestinal bleeding, and acute-on-chronic liver failure (ACLF) was made using criteria reported elsewhere. Acute impairment of kidney function (AKI) was defined using the AKIN criteria adapted to patients with cirrhosis. During admission, complications of cirrhosis were managed according to international guidelines.

Plasma Fatty-acid binding protein measurements. Plasma samples were obtained in the morning, approximately at 9 a.m., and centrifuged at 2000 rpm for 10 minutes and the supernatant was stored at –80 °C until analysis. L-FABP1, I-FABP2 and A-FABP4 were measured with the human L-FABP1 ELISA kit (Hycult Biotech; Uden, The Netherlands), the human I-FABP2 ELISA kit (Hycult Biotech; Uden, The Netherlands) and the Quantikine ELISA human A-FABP4 kit (R&D Systems, Minneapolis, USA), respectively. Interleukin-6 (IL-6) was measured with human ELISA IL-6 kit (Diasource; Louvain-la-Neuve, Belgium). Coefficients of inter-assay and intra-assay variation for plasma FABPs were lower than 10 and 15%, respectively.

Hepatic Gene expression of FABPs. Mouse models of liver injury. Mice aged 8–10 weeks were subjected to a chronic liver injury model by injecting carbon tetrachloride (CCl4) intraperitoneally (Sigma-Aldrich; diluted 1:4 in corn oil) at dose of 0.5 ml/kg body weight twice per week for a total of 5 injections (n = 4). Control mice (n = 3) were given vehicle (corn oil, Sigma-Aldrich). We also performed a model of acute-on-chronic liver injury by the administration of lipopolysaccharide (LPS, Sigma-Aldrich) 10 mg/kg on the chronic damage caused by CCl4. Animal procedures complied with the institution's guidelines, received human care and were approved by the ethics committee of the University of Barcelona and all experiments were performed in accordance with relevant guidelines and regulations.
**Murine hepatic cell sorting.** Different hepatic cell populations were isolated from the livers of mice treated with CCI4 and LPS. Cells were isolated as previously described. Briefly, after two-step collagenase-pronase perfusion of livers followed by Nycodeinz density gradient centrifugation, obtained cells were incubated with CD3- Alexa Fluor 700 (T cells), F4/80-Alexa Fluor 647 (Serotec) (macrophages), APC-APC (eBioscience, Affymetrix, San Diego, CA, USA) (neutrophils), and HSC were purified by vitamin A–based flow cytometry. All samples were purified by high-speed sorting using a FACS-Aria cell sorter (Becton, Dickinson and Company, BD, New Jersey, NJ, USA).

**mRNA isolation and gene expression assay.** mRNA was isolated from human and murine liver tissues using Trizol and following manufacturer’s manual instructions (Invitrogen, Carlsbad, CA, USA). mRNA from sorted cells was harvested by using the QIAGEN RNeasy MICROKit (QIAGEN GmbH, Hilden, Germany). mRNA levels were evaluated by quantitative real time PCR on an ABI 7900HT cycler (Applied Biosystems) using Taqman gene expression assays (Life technologies). Individual gene expression was normalized to 18 s or GAPDH. Relative expression was calculated using the comparative Ct method (2 \(^{-\Delta\Delta Ct}\)).

**Immunohistochemistry.** Human paraffin embedded liver sections were used for immunohistochemistry using the Leica Microsystems’ Bond-Max automated immunostainer together with the Bond Polymer Refine Detection System (Leica Microsystems, Spain). Briefly, samples were deparaffinized and antigen retrieval performed in citrate buffer (pH 6, 20 minutes). Sections were then immunostained with primary antibody to FABP4 (dilution 1:1500, Abcam, UK) for 1 hour at room temperature, developed with diaminobenzidine and counterstained with hematoxylin.

**Statistical analysis.** Results for continuous variables were expressed as median and interquartile range. Counts and percentages were used for the description of the categorical variables. Comparisons between two independent groups were made with the t-test (previously checking the hypothesis of variance homogeneity) for continuous normal-distributed variables. The Mann-Whitney U test was carried out for continuous non-normal distributed variables in the case of 2 independent groups, whereas the Kruskal-Wallis test was performed when comparing a higher number of groups. Comparisons of categorical variables among groups were made with chi-squared test or Fisher test if appropriate.

Survival analyses were performed with Kaplan-Meier curves and log-rank test. Multivariate logistic regression models were fitted with all variables that were predictive of ACLF at univariate analysis to select main factors independently associated with ACLF. Multivariate cox-regression analysis was performed to investigate independent predictor factors of three-month survival. Variables with skewed distribution were log-transformed before being included in the multivariate analysis model. Regarding plasma A-FABP4 levels, the variable followed a non-normal distribution and the linearity was lacking, being the risk for the fourth quartile, if not less than for third quartile, at least is quite similar to it. Therefore, in order not to overestimate the risk for the last quartile we categorized the variable as median to include in the cox-regression analysis. The significance level for all statistical tests was set at 0.05 two-tailed. All statistical analyses were performed using SPSS 20.0 software.

**References**

1. Furuhashi, M. & Hotamisligil, G. S. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. *Nat. Rev. Drug Discov.* 7, 489–503 (2008).

2. Storch, J. & Thumser, A. E. Tissue-specific functions in the fatty acid-binding protein family. *J. Biol. Chem.* 285, 32679–32683 (2010).

3. Fuyuya, T. L. al. Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population. *Cardiovasc. Diabetol.* 13, 126 (2014).

4. Pelsers, M. M. A. L., Hermens, W. T. & Glatz, J. F. C. Fatty acid-binding proteins as plasma markers of tissue injury. *Clin. Chim. Acta* 352, 13–35 (2005).

5. Pelsers, M. M. A. L. et al. Liver fatty acid-binding protein as a sensitive serum marker of acute hepatocellular damage in liver transplant recipients. *Clin. Chem.* 48, 2055–7 (2002).

6. Schurink, M. et al. Intestinal Fatty Acid-Binding Protein as a Diagnostic Marker for Complicated and Uncomplicated Necrotizing Enterocolitis: A Prospective Cohort Study. *PLoS One* 10, e0121336 (2015).

7. Schellekens, D. H. S. M. et al. Plasma Intestinal Fatty Acid-Binding Protein Levels Correlate With Morphologic Epithelial Intestinal Damage in a Human Translational Ischemia-reperfusion Model. *J. Clin. Gastroenterol.* 48, 253–260 (2014).

8. Furuhashi, M., Furuhashi, M., Saitoh, S., Shimamoto, K. & Miura, T. Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases. *Clin. Med. Insights Cardiovasc. Diabetol.* 23, doi:10.4137/CMC.S17067 (2015).

9. Hotamisligil, G. S. & Bernlohr, D. A. Metabolic functions of FABPs—mechanisms and therapeutic implications. *Nat. Rev. Endocrinol.* 11, 592–605 (2015).

10. Huang, C.-L. et al. Serum adipocyte fatty acid-binding protein levels in patients with critical illness are associated with insulin resistance and predict mortality. *Crit. Care* 17, B22 (2013).

11. Bernardi, M., Moreau, R., Angelii, P., Schnabl, B. & Arroyo, V. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. *J. Hepatol.* 63, 1272–1284 (2015).

12. West, R., Lawson, M. & Geuking, M. Pathological bacterial translocation in liver cirrhosis. *J. Hepatol.* 60, 197–209 (2014).

13. Cazzaniga, M. et al. The systemic inflammatory response syndrome in cirrhotic patients: Relationship with their in-hospital outcome. *J. Hepatol.* 51, 475–482 (2009).

14. Albillos, A., Lario, M. & Alvarez-Mon, M. Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance. *J. Hepatol.* 61, 1385–1396 (2014).

15. Charlton, M. et al. Differential expression of lumican and fatty acid binding protein-1: New insights into the histologic spectrum of nonalcoholic fatty liver disease. *Hepatology* 49, 1375–1384 (2009).

16. Milner, K.-L. et al. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. *Hepatology* 49, 257–264 (2009).

17. Schroeder, F. et al. Role of fatty acid binding proteins and long chain fatty acids in modulating nuclear receptors and gene transcription. *Lipids* 43, 1–17 (2008).
18. Makowski, L. & Hotamisligil, G. S. The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. *Carr. Opin. Lipidol.* **16**, 543–8 (2005).
19. Makowski, L., Brittingham, K. C., Reynolds, J. M., Suttles, J. & Hotamisligil, G. S. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. *J. Biol. Chem.* **280**, 12888–95 (2005).
20. Hui, X. et al. Adipocyte Fatty Acid-binding Protein Modulates Inflammatory Responses in Macrophages through a Positive Feedback Loop Involving c-Jun NH2-terminal Kinases and Activator Protein-1. *J. Biol. Chem.* **285**, 10273–10280 (2010).
21. Cao, H. et al. Adipocyte Lipid Chaperone aP2 Is a Secreted Adipokine Regulating Hepatic Glucose Production. *Cell Metab.* **17**, 768–778 (2013).
22. Kaes, B. M. et al. Cardiometabolic Correlates and Heritability of Fetuin-A, Retinol-Binding Protein 4, and Fatty-Acid Binding Protein 4 in the Framingham Heart Study. *J. Clin. Endocrinol. Metab.* **97**, E1943–E1947 (2012).
23. Bolites, A., Movita, D., Boonstra, A. & Woltman, A. M. The role of Kupffer cells in hepatitis B and hepatitis C virus infections. *J. Hepatol.* **61**, 660–671 (2014).
24. Baffy, G. Kupffer cells in non-alcoholic fatty liver disease: The emerging view. *J. Hepatol.* **51**, 212–223 (2009).
25. Grenbæk, H. et al. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF). *J. Hepatol.* **64**, 813–822 (2016).
26. Moreau, R. et al. Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. *Gastroenterology* **144**, 1426–1437.e9 (2013).
27. Solé, C. et al. Characterization of Inflammatory Response in Acute-on-Chronic Liver Failure and Relationship with Prognosis. *Sci. Rep.* **6**, 32341 (2016).
28. Claria, J. et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. *Hepatology* **64**, 1249–1264 (2016).
29. Layne, M. D. Role of macrophage-expressed adipocyte fatty acid binding protein in the development of accelerated atherosclerosis in hypercholesterolemic mice. *FASEB J.*, doi:10.1096/fj.01-0374fje (2001).
30. de Franchis, R. Expanding consensus in portal hypertension. *J. Hepatol.* **63**, 743–752 (2015).
31. McSweeney, S. et al. Clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. *J. Hepatol.* **53**, 397–417 (2010).
32. American Association for the Study of Liver Diseases & European Association for the Study of the Liver. Hepatic encephalopathy and chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. *J. Hepatol.* **61**, 642–59 (2014).
33. Angeli, P. et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. *J. Hepatol.* **62**, 968–974 (2015).
34. Huelin, P. et al. Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acute-on-Chronic Liver Failure. *Clin. Gastroenterol. Hepatol.*, doi:10.1016/j.cgh.2016.09.016 (2016).
35. Afò, S. et al. CCL2 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. *Gut* **63**, 1782–1792 (2014).

**Acknowledgements**

We would like to thank Dr Miquel Brugueruela and Dr Daniel Martinez for their support in immunohistochemical analysis. Some of the work mentioned has been supported by grant awarded to PG (FIS P11/00330 and FIS PI16/00043). Fondos de Investigación de Salud Carlos III integrated in the Plan Nacional I + D + I and co-funded by ISCIII-Subdirección General de Evaluación and European Regional Development Fund FEDER. Agencia de Gestión d’Ajuts Universitaris i de Recerca (AGAU) 2014/SGR 708 PG is a recipient of an ICREA Academia Award. Isabel Graupera was supported by a grant from the Plan Estatal I + D + I and Instituto Carlos III (Rio-Hortega fellowship: CM14/00122). Mar Coll was supported by a grant from the Plan Estatal I + D + I and Instituto Carlos III (Sara Borrell fellowship: CS/00298). Elisa Pose was supported by a PHDMD4 fellowship (PHDMD4/2016), Patricia Huelin was supported by a grant from the University of Barcelona (APIF2015), Cristina Solé was supported by a grant from the Instituto de Salud Carlos III (PFIS fellowship FI14/00227).

**Author Contributions**

The authors listed above have all contributed to this manuscript and approve the version of this submission. I.G. contributed to the conception and design of the study, acquisition of data, the statistical analysis and interpretation of the data and drafting the manuscript; M.C., E.P. and D.B. participated in the realization of the experimental analysis, interpretation of the data and drafting the manuscript. C.H., S.P., E.S., F.H., C.S., R.M., G.P., N.F. and A.J. participated in acquisition of data and the analysis and interpretation of the data and statistical analysis as well as in the critical revision of the paper; M.M. and C.V. participated in the generation of data, analyses of the results, interpretation of data, and/or critical revision of the manuscript for important intellectual content. P.G. participated in the study concept, interpretation of the data, drafting the manuscript, critical revision of the manuscript for important intellectual content, obtained funding and study supervision.

**Additional Information**

**Supplementary information** accompanies this paper at doi:10.1038/s41598-017-01709-0

**Competing Interests:** Pere Ginès declares that he has received research funding from Ferring Pharmaceuticals, Grifols S.A., and Sequana Medical. He has participated on Advisory Boards for Noorik, Ikaria, Ferring Pharmaceuticals, Promethera and Sequana Medical. All other authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
